Vyne Therapeutics Stock Intrinsic Value – Director Lepore Shows Confidence in VYNE Therapeutics, Buys 13K Shares

November 21, 2023

☀️Trending News

VYNE ($NASDAQ:VYNE) Therapeutics is an innovative biopharmaceutical company that is leading the way in developing treatments for a variety of serious conditions. Recently, the company reported that Director Lepore has acquired 13,000 shares of the company’s stock, demonstrating his confidence in VYNE Therapeutics and its mission. This is a strong vote of confidence for the company, and it sends a message to the market that VYNE Therapeutics is on its way to becoming a leader in the biopharmaceutical industry. This news serves as a reminder that the future of health care is being shaped by innovative biopharmaceutical companies like VYNE Therapeutics.

With a proven track record of developing effective treatments, VYNE Therapeutics is well-positioned to become a leader in the industry. As Director Lepore continues to show faith in VYNE Therapeutics, investors and analysts are likely to take notice of the company’s progress. With Director Lepore’s recent acquisition of 13,000 shares, VYNE Therapeutics is poised for further success in the future.

Market Price

This shows that Lepore has confidence in the company, which is likely the reason behind his purchase. The stock of VYNE THERAPEUTICS has been steadily rising since early February, and Lepore’s purchase is a bullish sign for investors. Looking forward, it will be interesting to see how the company performs and if others follow Lepore’s lead in investing in the company. Live Quote…

About the Company

  • Industry Classification
  • Key Executives
  • Ownership (Institutional/ Fund Holdings)
  • News Feed
  • Income Snapshot

    Below shows the total revenue, net income and net margin for Vyne Therapeutics. More…

    Total Revenues Net Income Net Margin
    0.35 -32.21 -8328.0%
  • Income Statement Reports (Yearly/ Quarterly/ LTM)
  • Income Supplement
  • Growth Performance
  • Cash Flow Snapshot

    Below shows the cash from operations, investing and financing for Vyne Therapeutics. More…

    Operations Investing Financing
    -25.02 5 -0.06
  • Cash Flow Statement (Yearly/ Quarterly/ LTM)
  • Cash Flow Supplement
  • Balance Sheet Snapshot

    Below shows the total assets, liabilities and book value per share for Vyne Therapeutics. More…

    Total Assets Total Liabilities Book Value Per Share
    19.27 7.76 3.51
  • Balance Sheet (Yearly/ Quarterly)
  • Balance Sheet Supplement
  • Key Ratios Snapshot

    Some of the financial key ratios for Vyne Therapeutics are shown below. More…

    3Y Rev Growth 3Y Operating Profit Growth Operating Margin
    -72.3% -8487.9%
    FCF Margin ROE ROA
    -7066.4% -130.5% -97.5%
  • Income Statement Ratios
  • Balance Sheet Ratios
  • Cash Flow Ratios
  • Valuation Ratios
  • Other Ratios
  • Other Supplementary Items
  • Analysis – Vyne Therapeutics Stock Intrinsic Value

    At GoodWhale, we have conducted an analysis of VYNE THERAPEUTICS‘ financials. Our proprietary Valuation Line has determined that the intrinsic value of a VYNE THERAPEUTICS share is around $4.7. Currently, the stock is being traded at $4.0, which is a fair price but still undervalued by 14.6%. We believe that this company is a good opportunity to invest in at this time, given the discrepancy between intrinsic and stock value. More…

  • Star Chart Analysis
  • Valuation Analysis

  • Peers

    The pharmaceutical industry is currently witnessing intense competition between VYNE Therapeutics Inc and several of its major competitors, including PhaseBio Pharmaceuticals Inc, Inozyme Pharma Inc, and Neovacs SA. These companies are all competing to bring innovative solutions to the health care industry and strive to be the first to market their products. As each company works to develop cutting-edge treatments and therapies, the competition promises to be fierce and compelling.

    – PhaseBio Pharmaceuticals Inc ($OTCPK:PHASQ)

    PipelineBio Pharmaceuticals Inc is a leading biopharmaceutical company based in California. The company focuses on the development and delivery of innovative treatments for serious diseases, such as cancer and rare genetic disorders. As of 2023, it has an impressive market capitalization of 39.89k and an impressive Return on Equity of 58.1%. PipelineBio is committed to providing effective solutions to the most formidable healthcare challenges. The company’s core competency lies in its ability to build and develop novel drugs with high potency and long-term effectiveness. PipelineBio is also constantly expanding its existing products and services to meet the growing demands of the healthcare sector.

    – Inozyme Pharma Inc ($NASDAQ:INZY)

    Inozyme Pharma Inc is a biotechnology company focused on developing treatments for rare genetic diseases. As of 2023, the company has a market cap of 262.32M and a Return on Equity (ROE) of -33.91%. The market capitalization of a company is the value of its outstanding shares, and it indicates the size of the company in terms of market value. The ROE, on the other hand, measures how well the company is performing in terms of its ability to generate profits from its equity investments. Inozyme Pharma Inc’s market capitalization indicates that it is a medium sized company, and its negative ROE implies that it is not doing as well as other companies in its sector.

    – Neovacs SA ($BER:0LWA)

    Neovacs SA is a biotechnology company that develops immunotherapies to treat autoimmune diseases such as systemic lupus erythematosus, rheumatoid arthritis, and psoriasis. As of 2023, Neovacs SA has a market cap of 745.47k and a Return on Equity (ROE) of -16.96%. This indicates that the company is currently not generating a strong return on its equity investments, but has a relatively small market capitalization. It is likely that investors are waiting for Neovacs SA to unlock the potential of its treatments before investing in the company.


    VYNE Therapeutics Inc., a biopharmaceutical company focused on the development and commercialization of novel therapies, has recently seen an increase in investment activity. Director Michael Lepore has purchased 13,000 shares in the company, indicating confidence in the future of VYNE. This development further reflects the confidence of the market in the potential of VYNE’s pipeline products.

    Analysts are optimistic about VYNE due to its robust clinical development program and initiatives to expand its commercial capabilities. Investors should keep a close watch on VYNE as it seeks to bring new treatments to market and ramp up its presence in the biopharmaceutical arena.

    Recent Posts

    Leave a Comment